MCMark CottonMD, PhDSlidesetHIVGlobal HIV Clinical Forum 2017Pediatric use of Integrase Inhibitors- Mark Cotton, MD, PhDView Slideset
DBDavid BackPhDSlidesetHIVGlobal HIV Clinical Forum 2017Clinical Pharmacology related considerations- David Back, PhDView Slideset
SlidesetHIVGlobal HIV Clinical Forum 2017Resistance Characteristics of Integrase Inhibitors- Charlotte Charpentier, PharmD, PhDView Slideset
SlidesetHIVGlobal HIV Clinical Forum 2017Potential role of Integrase Inhibitors in resource-limited settings- Gary Maartens, MDView Slideset
SlidesetHIVGlobal HIV Clinical Forum 2017Basic Science of Integrase Inhibitors - Recent Advances- Francois Clavel, MDView Slideset
APAnton PozniakMD, FRCPVideoHIVGlobal HIV Clinical Forum 2017Optimizing Clinical Utility of Integrase Inhibitors | Anton Pozniak, MD, FRCPView Video
PCPedro CahnMD, PhDVideoHIVGlobal HIV Clinical Forum 2017Clinical Case -Reduced Drug Regimen | Pedro Cahn, MD, PhDView Video
PCPep CollMD, MSVideoHIVGlobal HIV Clinical Forum 2017The Role of Integrase Inhibitors during HIV prevention | Pep Coll, MDView Video
SWSharon WalmsleyCM, MD, FRCPCVideoHIVGlobal HIV Clinical Forum 2017https://academicmedicaleducation.com/meeting/global-hiv-clinical-forum-2017/video/clinical-pharmacology-related-considerations-davidView Video
DBDavid BackPhDVideoHIVGlobal HIV Clinical Forum 2017Clinical Pharmacology related considerations | David Back, PhDView Video
VideoHIVGlobal HIV Clinical Forum 2017Potential role of Integrase Inhibitors in resource-limited settings | Gary Maartens, MDView Video
VideoHIVGlobal HIV Clinical Forum 2017Clinical Case - Transmitted/Acquired Resistance Related | Michelle Moorhouse, MBBChView Video
